Neuroscientist Torsten Falk's research indicates that the anesthetic ketamine eases dyskinesia in rodents and also in five Parkinson's patients who were already taking it for pain relief.
Repurposing ketamine for dyskinesia could get it to patients quicker. It's already been safety tested at higher doses than Falk plans to test.